Jindan Yu, Ph.D.
Affiliations: | 2004 | University of Michigan, Ann Arbor, Ann Arbor, MI |
Area:
Genetics, Molecular Biology, Biostatistics BiologyGoogle:
"Jindan Yu"Parents
Sign in to add mentor| Anand Swaroop | grad student | 2004 | University of Michigan | |
| (Transcript profiling of the cone-only Nrl-knockout retina using custom cDNA-microarrays: Identification of novel targets of Nrl and of signaling pathways involved in photoreceptor function.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Ferrari MG, Jimenez-Uribe AP, Wang L, et al. (2023) Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target. Oncogene |
| Gritsina G, Fong KW, Lu X, et al. (2023) Chemokine receptor CXCR7 activates AURKA and promotes neuroendocrine prostate cancer growth. The Journal of Clinical Investigation |
| Ferrari M, Wang L, Hoeppner L, et al. (2023) Myeloid differentiation factor-2/LY96, a new predictive biomarker of metastasis in prostate cancer: Clinical implications as a potential therapeutic target. Research Square |
| Lin Z, Agarwal S, Tan S, et al. (2023) Palmitoyl acyltransferase ZDHHC7 inhibits androgen receptor and suppresses prostate cancer. Oncogene |
| Xie W, Agarwal S, Yu J. (2023) Ferroptosis: the vulnerability within a cancer monster. The Journal of Clinical Investigation. 133 |
| Gritsina G, Yu J. (2023) CXCR7 as a novel therapeutic target for advanced prostate cancer. Oncogene |
| Fong KW, Zhao JC, Lu X, et al. (2022) PALI1 promotes tumor growth through competitive recruitment of PRC2 to G9A-target chromatin for dual epigenetic silencing. Molecular Cell. 82: 4611-4626.e7 |
| Wang X, Brea L, Lu X, et al. (2022) FOXA1 inhibits hypoxia programs through transcriptional repression of HIF1A. Oncogene |
| Lu X, Fong KW, Gritsina G, et al. (2022) HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer. Nature Genetics |
| Rodríguez Y, Unno K, Truica MI, et al. (2022) A genome-wide CRISPR activation screen identifies PRRX2 as a regulator of enzalutamide resistance in prostate cancer. Cancer Research |